InSilico's mission is to put our genomes directly into the hands of the people who can use them to improve our health and lifestyle, for our own benefit, and under our own terms.
Becoming the worldwide genomic hub providing biologists with central, transparent access to sequencers, analysis tools, genome repositories, and collaboration.
An agile and experienced team supported by product, market and business mentors.
David Weiss Founder & CEO
Bioengineer, PhD in bioinformatics ULB, did research at Broad Institute and MIT.
Alain Coletta Founder & Exec. director
Molecular Biologist, PhD in Bioinformatics from University of Manchester.
Robin Duqué Full Stack Developer
Industrial Engineer, founding team member with 5 year experience building InSilico DB. Previously, software engineer @ ING (banking).
James Cauwelier Systems Architect
Master in Biotechnology. Previously VP of engineering @Sparkcentral (SV startup that raised $18M).
Jaro Vanderheijden Web Developer
Main front-end developer, 2 years experience on InSilico DB.
Virginie de Schaetzen Biocurator
MD, dermatologist. 5 year experience in InSilico DB.
Lionel Perl President of the Board
Investment banker and Private Equity investor, Member of the Board of Ageas insurance group.
Andréa Goldsztein Administrative Assistant
PhD in Molecular Biology Experience in R&D subsidy management.
InSilico Genomics’ key investors from IT, Biotech and Finance.
Shareholders from the IT field
Harold Mechelynck and Thierry Pierson, founders of Ogone, an on-line financial transactions settlement operation sold for 360 million € to French group Ingenico.
Shareholders from the academic field
Université Libre de Bruxelles and management team.
Shareholders from the medical Field
Jean Stephenne, previous President and
General Manager of GlaxoSmithKline
Biologicals, advisor to the Belgian
government in Life Sciences, active investor
in biotech companies.
Désiré Collen, MD, Professor Emeritus at Catholic University of Leuven, Founder of Thrombogenics, via his private foundation Life Science Research Partners.
Jean Marie Delwart, active and serial investor in biotech companies, via his private holding Belgocodex.
Shareholders from the field of finance
Pierre Drion, investment banker, ex
Partner of Petercam, one of Belgium’s
largest investment banks, Chairman of
Olivier van der Rest, Chairman of Aliaxis, a 2 billion revenues company active in construction materials, via his private holding Catalpa.